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Senescence, the state of irreversible cell-cycle arrest, plays paradoxical albeit important roles in vivo: it protects
organisms against cancer but also contributes to age-related loss of tissue function. The DNA damage response
(DDR) has a central role in cellular senescence. Not only does it contribute to the irreversible loss of replicative
capacity but also to the production and secretion of reactive oxygen species (ROS), and bioactive peptides
collectively known as the senescence-associated secretory phenotype (SASP). Both ROS and the SASP have been
shown to impact on senescence in an autocrine as well as paracrine fashion; however, the underlying mechanisms
are not well understood. In this review we describe our current understanding of cellular senescence, examine in
detail the intricate pathways linking the DDR, ROS and SASP, and evaluate their impact on the stability of the
senescent phenotype.
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Introduction
Cellular senescence, the state of irreversible cell cycle
arrest described by Hayflick and Moorhead [1] over 50
years ago, remains an intriguing biological process.
Senescence is characterised by dramatic changes in cell
morphology, including increased cellular volume and
flattening of the cytoplasm [2]. The senescent pheno-
type also results in changes in nuclear structure, gene
expression, protein processing and metabolism, and
resistance to apoptosis [3-6].
Whether senescence exists to any significant extent
in vivo has been the subject of a longstanding debate [7].
In the past decade, remarkable advances have been made
demonstrating that senescence plays an important role
in vivo. Several studies suggest that senescence can act
as a tumour suppressor mechanism [8,9]. On the other
hand, numerous lines of evidence indicate that senes-
cence can, in the long run, have adverse effects, by
impairing organ regeneration and releasing a host of
bioactive molecules, including reactive oxygen species
(ROS) and a wide variety of pro-inflammatory cytokines,* Correspondence: joao.passos@ncl.ac.uk
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distribution, and reproduction in any mediumchemokines and growth factors (collectively referred to as
the senescence-associated secretory phenotype (SASP)).
Senescent cells containing telomere-induced foci have
been shown to increase with age in the skin of baboons,
which have similar telomere length to humans and ab-
sence of telomerase activity [10]. In mice, cells bearing
senescent markers have been reported to increase with
age in a variety of tissues [11-13], including post-mitotic
neurons [14]. Moreover, senescent cells have been asso-
ciated with several age-related diseases, such as diabetes
[15] and atherosclerosis [16]. While noteworthy, these
data do not provide causality. A major challenge in the
field has been to determine if and how senescent cells
contribute to age-related tissue dysfunction, or if they
merely correlate with it.
Mounting evidence indicates that activation of pathways
involved in cellular senescence impacts on mammalian
lifespan [17-19]. Recently, the van Deursen group has
shown that inducible elimination of p16Ink4a-positive
senescent cells from the eye, adipose and skeletal tissues in
the BubR1 progeroid mouse model delayed acquisition of
age-related pathologies in these tissues. They showed that
elimination of p16Ink4a-positive cells also attenuated the
progression of already established age-related disorders,
suggesting that cellular senescence may have a causal role
in age-related tissue impairment [20].entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion of senescence have been identified, it is still unclear
how a cell “commits” to becoming irreversibly arrested.
Recent studies have revealed that the SASP, as well as
mitochondrial/metabolic alterations, may contribute to
the reinforcement of the growth arrest via a series of
positive feedback loops involving a persistent activation
of the DNA damage response (DDR) [21-23].
The aim of this review is to describe the current un-
derstanding of cellular senescence, providing special
focus on the intricate pathways that link the nucleus,
mitochondria and secreted proteins, and contribute to
the stability of the senescent phenotype.
Telomeres and the stabilisation of cellular senescence
Telomeres are regions of DNA and associated proteins
present at the end of linear chromosomes; in vertebrates
they are tandem repeats of the sequence TTAGGG [24].
Telomeres are bound by a group of telomere-associated
proteins known as the “shelterin” complex [25]. These pro-
teins are thought to arrange telomeric DNA into a loop
structure known as the T-loop [26]. This structure was first
visualised in purified telomere restriction fragments using
electron microscopy, and it is proposed to prevent the acti-
vation of a DDR by hiding the exposed DNA ends. The
shelterin complex is comprised of six proteins: TRF1, TRF2
and POT1, which recognise the telomeric repeat sequence,
and additional proteins TIN2, TPP1 and Rap1 [25].
Telomere shortening is probably the best studied
mechanism driving cellular senescence. It mainly occurs
during cell division due to the inability of the DNA rep-
lication machinery, specifically DNA polymerase, to syn-
thesise in a 3′-5′ direction leading to the incomplete
replication of the lagging strand. It has been shown
that telomere shortening contributes causally to cellu-
lar senescence, since overexpression of telomerase, an
enzyme able to maintain telomere length, resulted
in cell immortalisation [27]. Mouse models, where
telomere function has been compromised, strongly
support a role for senescence (and telomeres) in the
ageing process. Telomerase knock-out (mTERC−/−)
mice which carry a homozygous deletion of the RNA
component of telomerase [28] show a progressive
generation-dependent telomere shortening, which results
in both cell-cycle arrest and apoptosis [29]. Telomere
dysfunction in mTERC−/− mice has been shown to
limit stem cell function, regeneration, organ homeosta-
sis and lifespan [30].
It is believed that the progressive loss of telomere re-
peats destabilises T-loops [26] and, as a consequence, in-
creases the probability of telomere uncapping (that is,
loss of “shelterin”). Uncapping of telomeres, whether by
inhibition of TRF2 or telomere shortening, has been
shown to activate the DDR in a manner similar to DNAdouble strand breaks (DSBs) [31,32]. The DDR can elicit
a transient cell-cycle arrest, allowing sufficient time for
the cellular repair machinery to act and repair the DNA
damage [33]. However, if the damage is irreparable, the
arrest can become permanent. This response is initiated
by the phosphatidylinositol 3-kinase-like protein kinases
ATM and ATR, which phosphorylate proteins such as
H2A.X and NBS1, and downstream kinases CHK1 and
CHK2, which ultimately activate p53 and p21 proteins
[34]. Several groups have reported that senescence is
characterised by a persistent activation of the DDR,
which is necessary for both the development and stabi-
lity of the phenotype [21,35].
One important question is: what contributes to a per-
sistent DDR during cellular senescence? Recent work
has highlighted the importance of telomeres in the
maintenance of senescence. It has been demonstrated
that DNA damage at telomeres can occur as a conse-
quence of genotoxic and oxidative stress, and that this
damage is mostly irreparable [13,36]. In order to estab-
lish whether a telomeric location is necessary for foci to
persist, using live-cell imaging, our group has tracked
the lifespan of DNA damage foci using a AcGFP-53BP1c
fusion protein in combination with a fluorescently
labelled PNA probe that specifically tags telomere re-
peats. Using this method it was found that the majority
of long-lived foci in stress-induced senescent cells co-
localise with telomeres [13], which suggests that they are
major contributors to a persistent DDR.
These findings raise questions regarding how the cel-
lular repair machinery distinguishes telomeres and DSBs.
Non-homologous end joining (NHEJ) is strongly inhib-
ited in telomeric regions, perhaps as a mechanism to
prevent end-to-end fusions [37]. NHEJ is the major path-
way for the repair of DSBs. Moreover, displacement of
TRF2 from telomeres by overexpression of TRF2ΔBΔM, or
conditional deletion of TRF2, has been shown to result in
telomere fusions [37-39]. It has also been demonstrated
in vitro that TRF2 and its binding partner RAP1 are re-
quired to prevent NHEJ-dependent telomeric DNA fusions
by inhibiting DNA-PK and ligase IV mediated end-joining
[40]. Consistent with these data, Fumagalli and colleagues
have shown in budding yeast that induction of a DNA DSB
adjacent to a telomeric sequence impairs the recruitment of
ligase IV to the site of damage [36]. This suggests that da-
mage at telomeres, occurring in the presence of sufficient
shelterin components including TRF2, may elicit a persis-
tent DDR due to inhibition of repair. In accordance with
this hypothesis, it has been shown recently that during rep-
licative senescence of human fibroblasts, telomeres positive
for DDR retain both TRF2 and RAP1 and are not asso-
ciated with end-to-end fusions [41].
Recent studies have shown that the role of telomeres
in senescence may extend beyond attrition due to
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signals cause replication fork stalling, resulting in telo-
meric DNA damage accumulation, activation of a DDR
and consequently senescence [42]. However, it has been
reported that in both replicative and stress-induced sen-
escent cells, 50% of DNA damage foci can be found in
non-telomeric regions of the genome and are short-
lived. Live-cell imaging studies have shown that these
short-lived foci are maintained in relatively constant
numbers per cell and that new foci are regularly being
created during senescence [13,21]. Moreover, data indi-
cate that these foci are mainly the result of ROS produc-
tion during senescence and contribute to some degree to
the stability and development of the phenotype. Consis-
tently, following the activation of a DDR, inhibition of
ROS production results in a small fraction of cells being
able to resume proliferation [21].
Therefore, it is highly likely that both telomeric and
non-telomeric regions are contributors to the senescent
phenotype (Figure 1); however, their relative contribu-
tion towards senescence signalling is experimentally very
difficult to dissect.
Importantly, mechanisms other than the DDR have been
shown to impact on the stability of the senescent pheno-
type. In several types of cells, senescence is accompanied by
drastic changes in chromatin organisation, such as forma-
tion of senescence-associated heterochromatic foci, whichFigure 1 Both telomeric and non-telomeric DNA damage contribute t
telomeres is distinct from that throughout the genome; it is irreparable du
proteins, known as the “shelterin” complex. This contributes to a permanen
short-lived DDR foci by elevated reactive oxygen species (ROS) may equally
dynamic equilibrium between damage induction and repair can be maintaare dependent on the p16/Rb pathway [6]. Senescence-
associated heterochromatic foci have been shown to
accumulate on the promoters of cell-cycle genes during sen-
escence, and their occurrence has been shown to correlate
with the irreversibility of the senescent phenotype [6,43].
Involvement of reactive oxygen species in the
stabilisation of cellular senescence
ROS are likely to be involved in both the induction and
stabilisation of cellular senescence: several studies have
shown that ROS can accelerate telomere shortening
[44], and can damage DNA directly and thus induce a
DDR and senescence [45-47] (Figure 2a). ROS have been
implicated in organismal ageing, with countless reports
of associations between oxidative damage and the ageing
process [48-50]; however, genetically manipulated animal
models where mitochondrial function and oxidative stress
were targeted have generated conflicting results [51].
Several studies have shown that cellular senescence is
characterised by mitochondrial dysfunction contributing to
metabolic inefficiency and elevated ROS [52-56]. Elevated
ROS levels have been associated with replicative, stress-
and oncogene-induced senescence [8,45,55,57].
Evidence indicates that activation of major down-
stream effectors of the DDR in senescence result in ele-
vated ROS. Activation of a DDR by genotoxic stress or
telomere uncapping [21], over-expression of activatedo the stabilisation of cellular senescence. DNA damage at
e to the repression of DNA repair pathways by telomere bound
t DNA damage response (DDR). However, continuous generation of
contribute to the maintenance of the phenotype, as long as a
ined.
Figure 2 Two different models by which reactive oxygen species can impact on cellular senescence. (a) Reactive oxygen species (ROS)
produced via mitochondrial and non-mitochondrial sources can induce genomic DNA damage and accelerate telomere erosion/damage, both of
which contribute to activation of a DNA damage response (DDR). (b) ROS can act as signalling molecules in senescence: activation of “senescence
signals” has been shown to result in increased ROS generation (mitochondrial and non-mitochondrial). ROS has been shown to impact on a
variety of pathways which may help stabilise the senescence growth arrest. (c) Simplified feedback loop model involving ROS and DNA damage.
Telomere uncapping or general DNA damage triggers a DDR which culminates through yet unidentified processes to ROS generation. ROS
generation leads to additional DNA damage to the genome, stabilising the DDR and leading to a stable senescence arrest.
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[62] all resulted in elevated ROS generation. In most of
the above reported cases treatment with antioxidants,
such as N-acetyl cysteine, were able to prevent the cell-
cycle arrest supporting a causal role for ROS in the
process (Figure 2b).
These data indicate that elevated ROS are a conse-
quence of the activation of the senescence programme
and has led to the suggestion that ROS may act as
signalling molecules during cellular senescence [63].
However, mechanistically it is still unclear how these
pathways contribute to mitochondrial dysfunction and
ROS generation. Takahashi and colleagues, using human
fibroblasts expressing a temperature-sensitive simian
virus 40 large T antigen, connected p16 with ROS
production via protein kinase Cδ signalling [62]. Protein
kinase Cδ has been shown to activate a non-mitochondrial
source of ROS, generated by NADPH-oxidase through
phosphorylation of p47phox, an essential component of
NADPH oxidase [64]. Consistent with this study, NADPH
oxidases have been shown to limit the replicative life-
span of human endothelial cells in culture via ROS
generation [65].Oncogene-induced senescence has been associated
with mitochondrial dysfunction and ROS production,
which is dependent on intact p53 and Rb tumour sup-
pression pathways. Mitochondrial dysfunction resulted
in the loss of ATP and activation of AMPK; in addition,
mitochondrial-derived ROS were shown to contribute to
the oxidation of DNA [66]. In a recent study, it was
shown that BRAFV600E-induced senescence was accom-
panied by the activation of pyruvate dehydrogenase,
which resulted in the enhanced use of pyruvate by the
tricarboxylic acid cycle followed by increased respiration
and ROS generation [59].
The role of p53 and p21 in ROS generation during
senescence is still not well understood. An association
between p53 and transcriptional activation of genes in-
volved in mitochondrial apoptosis has been demon-
strated [67], as well as a stress-induced translocation of
p53 to mitochondria resulting in increased outer mem-
brane permeabilisation [68]; however, a direct role of
mitochondrial p53 in cellular senescence has not yet
been demonstrated. In contrast, transcriptional regula-
tion of mitochondrial genes by p53 has been reported to
impact on mitochondrial function and contribute to
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sion of the Sco2 gene, which is required for the assembly
of the mitochondrial DNA-encoded COX II subunit
[69]. In late generation telomerase knock-out mice that
have critically short telomeres, activation of p53 has
been shown to repress the promoters of PGC-1α and
PGC-1β genes, master regulators of mitochondrial bio-
genesis and function, thereby contributing to decreased
mitochondrial function [70].
Knockdown of both p53 and p21 by RNA-mediated
interference has been shown to reduce ROS generation
in both telomere-dependent and -independent senes-
cence [21]. Our group has found that ROS levels in-
crease in senescent cells as a result of signalling through
p21, and feed back into DNA damage induction and the
DDR, generating a stable, self-sustaining feedback loop
(Figure 2c). This feedback loop persists even in irrevers-
ibly deep senescence. Moreover, p21 appears to be the
critical mediator between the DDR and MAPK and
transforming growth factor (TGF)-β stress-induced sig-
nalling cascades, which have been shown to contribute
to ROS generation [21,71,72]. Consistently, a p21 knock-
out rescued at least some accelerated ageing phenotypes
in telomerase (mTERC) knock-out mice [17], as well as
markers of oxidative stress and DNA damage foci [21].
ROS has also been shown to impact on the DDR and
ultimately senescence in a non-cell-autonomous fashion.
A recent study has shown that senescent cells can induce a
DDR in neighbouring cells via a gap junction-mediated
cell-cell contact and processes involving ROS [73].
Synergistic interactions between the senescence-associated
secretory phenotype and reactive oxygen species
during senescence
During senescence, another major contributor to the sta-
bilisation of the growth arrest is mediated by autocrine
signalling involving the secretion of bioactive, frequently
pro-inflammatory peptides, known as the SASP [74] or
senescence-messaging secretome [75]. The SASP in-
cludes several families of soluble and insoluble factors.
The soluble factors include signalling molecules such as
growth factors, inflammatory and immune-modulatory
cytokines and chemokines, whereas the insoluble factors
mainly comprise extracellular matrix components [76].
It has long been recognised that the primary function of
secreted factors is to allow inter- and intra-cellular com-
munication. However, the SASP has been found to play
a series of somewhat contradictory roles, with important
consequences for ageing and cancer. First, it can con-
tribute to the surveillance and elimination of senescent
cells by the immune system [77,78]. Second, it can be
pro-tumorigenic [74,79,80]; both cell culture experi-
ments and studies involving the co-transplantation of
senescent and cancer cells into recipient mice haveshown that senescent fibroblasts can stimulate the hyper-
proliferation of cancer cells, neoplastic progression and
tissue damage. Third, it can contribute to the reinforcement
of oncogene- or stress-induced senescence in a cell-
autonomous fashion [22,23]. Fourth, it can induce senes-
cence in neighbouring cells via a bystander effect both
in vitro and in vivo [81].
Mechanistically, it is still not entirely understood how
the SASP contributes to the reinforcement of senes-
cence; however, several lines of evidence suggest the
existence of synergistic interactions between the DDR,
ROS and inflammatory signals (Figure 3a). Kinetic ana-
lysis has shown that ROS levels increase 2 to 3 days fol-
lowing activation of a DDR [21], while the SASP occurs 7
to 10 days later [76]. Induction of both ROS and the SASP
in X-ray irradiation-induced senescence has been shown to
be dependent on activation of the DDR [21,35].
The nuclear factor (NF)-κB family of transcriptional
factors regulate expression of numerous genes involved
in a variety of cellular processes including stress re-
sponse and inflammation [82]. Importantly, activation of
NF-κB has been considered critical in chronic inflamma-
tory diseases by increasing the expression of the genes
for many cytokines, enzymes, and adhesion molecules
[83]. Increased NF-κB activity has been shown to play
an important role in senescence [84] and the SASP [85].
Recent investigations using progeroid mouse models
(models of premature ageing) driven by DNA damage
have reported that these mice have increased activation
of NF-κB driven chronic inflammation and senescence
[86,87]. Interestingly, in a murine model of XFE (xero-
derma pigmentosum F–excision repair) progeroid syn-
drome, Ercc1–/Δ mice, inhibition of NF-κB signalling not
only reduced the onset of several age-related patholo-
gies, but also both DNA and protein oxidation [87], sug-
gesting a potential link between inflammation and ROS
pathways.
Another link between ROS and the SASP during
senescence involves the p38 mitogen-activated protein
kinase (p38MAPK). p38MAPK has been shown to regu-
late the SASP in senescence mainly through NF-κB
transcriptional activity [85]. Similarly, the p38MAPK
pathway has been shown to be important for ROS gener-
ation in both stress-induced and replicative senescence
and for the stability of the DDR [21]. p16, an important
tumour suppressor gene which can be induced by
stresses other than DNA damage, has been linked to in-
creased ROS production [62]; however, less is known
about its impact on the SASP. The Campisi laboratory
has shown that ionising radiation or oncogenic RAS-
induced senescence developed a SASP regardless of
expression of p16, suggesting that these are two separate
pathways. However, the mechanisms behind it are not
yet understood [88].
Figure 3 Senescence is a multi-layered process involving interactions between the DNA damage response, reactive oxygen species
and senescence-associated secretory phenotype. (a) Initially, stressors such as telomeric and non-telomeric DNA damage can lead to activation
of a DNA damage response (DDR) and cell cycle arrest. Following activation of the DDR, p53, p21 and p38MAPK pathways have been shown to
enhance nuclear factor (NF)-κB transcriptional activity. NF-κB activation is both responsible for the senescence-associated secretory phenotype
(SASP) and can induce (and be activated) by reactive oxygen species (ROS). p16 has been shown to induce ROS generation via NADPH oxidases
[62]; however, it has been shown to be unrelated to the SASP [88]. Secretion of bioactive molecules such as ROS and SASP factors contribute
not only to reinforce senescence in an autocrine fashion, but also to induce senescence in neighbouring cells. (b) Components of the SASP (such as
IL-8, β-IFN and transforming growth factor (TGF)-β) have been shown to reinforce the senescence arrest via ROS through yet unidentified mechanisms
[21,22,89]. (c) NF-κB transcriptional activity has been shown to be dependent on the DDR and ROS. However, NF-κB activation has been shown to increase
ROS generation (via regulating expression of mitochondrial genes or antioxidant, pro-oxidant genes) [96,97]. DDF - DNA Damage Foci.
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senescence via increased ROS (Figure 3b). Acosta and
colleagues have shown that inhibition of CXCR2, a pro-
miscuous receptor that transmits signals from several
CXC chemokine family members (CXCLs), including IL-
8, delayed the onset of both replicative and oncogene-
induced senescence and led to decreased activation of a
DDR [22]. Mechanistically, the authors proposed that in-
hibition of CXCR2 reduced the DDR potentially by redu-
cing ROS. β-IFN has been shown to induce senescence
through ROS production and subsequent activation of
the DDR, which could be inhibited with the antioxidant
N-acetyl cysteine [89]. TGF-β, a family of secreted
peptides that regulate a variety of processes such as pro-
liferation, adhesion, migration, and differentiation in sev-
eral cell types, has also been implicated in senescence.Inactivation of TGF-β1 secretion in mouse keratinocytes
was sufficient to prevent oncogene-induced senescence
[90]. In human fibroblasts, blocking TGF-β1 type II recep-
tor (TGFBR2) activity has been shown to prevent Ultravio-
let B-induced senescence and hydrogen peroxide-induced
senescence [91,92]. Recently, it was demonstrated that the
TGF-β induced senescence in a paracrine fashion [81].
Interestingly, neutralising antibodies or chemical inhibitors
against the TGFBR2 have been shown to decrease ROS
production downstream of the DDR induced in a telomere-
dependent and -independent fashion [21].
Another potential link between the SASP and ROS is
the fact that several studies indicate that NF-κB, the
main regulator of the SASP, is also a major player in the
regulation of mitochondrial function and oxidative stress
(Figure 3c). Firstly, NF-κB is localised in mitochondria
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the regulation of mitochondrial encoded genes [94].
Bakkar and colleagues reported that activation of the
RelB subunit of NF-κB during myogenesis is important
for mitochondrial biogenesis [95]. More recently it was
demonstrated that IKKα and RelB regulate the transcrip-
tion co-activator PGC-1β, a master regulator of mitochon-
drial function, to promote oxidative muscle metabolism
[96]. Secondly, it has also been reported that NF-κB is
involved in the transcriptional regulation of both nuclear-
encoded anti-oxidant and pro-oxidant genes [97]. A recent
study in a mouse model of type II diabetes-induced cardiac
dysfunction has shown that enhanced NF-κB activity is
associated with increased oxidative stress. The authors
demonstrated that chemical inhibition of NF-κB alleviated
oxidative stress, improved mitochondrial structural in-
tegrity, and ultimately restored cardiac function in type
II diabetes [98].
In contrast, numerous reports have implicated ROS in
the activation of NF-κB [99]. Both DNA binding and trans-
activation by NF-κB have been shown to be strongly acti-
vated by H2O2 [100]. Mechanistically, evidence suggests
that ROS are both cause and consequence of NF-κB path-
way activation during senescence, making it challenging to
establish which process occurs first. Further work is needed
in order to understand the kinetics of activation of these
pathways during senescence.Conclusions
In addition to its previously documented role as a tumour
suppressive mechanism, recent evidence strongly implicates
cellular senescence in ageing and age-related diseases. Both
telomeric and non-telomeric DNA damage has been shown
to contribute to the phenotype, with ROS playing an im-
portant role in both the induction and stabilisation of sen-
escence. Moreover, the activation of the DDR, and the
MAPK and NF-κB pathways has been shown to contribute
to the regulation of both ROS and the SASP. Despite
accumulating evidence suggesting that ROS and the SASP
cooperate to induce and stabilise the senescent phenotype,
further research is necessary to mechanistically delineate
their interactions in regulating their response, and their
contributions to modulating the surrounding tissue micro-
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